- Home
- OMGA vs MAIA Comparison
OMGA vs MAIA Comparison
Compare OMGA & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OMGA
- MAIA
- Stock Information
- Founded
- OMGA 2017
- MAIA 2018
- Country
- OMGA United States
- MAIA United States
- Employees
- OMGA N/A
- MAIA N/A
- Industry
- OMGA Biotechnology: Pharmaceutical Preparations
- MAIA Biotechnology: Pharmaceutical Preparations
- Sector
- OMGA Health Care
- MAIA Health Care
- Exchange
- OMGA Nasdaq
- MAIA Nasdaq
- Market Cap
- OMGA 53.6M
- MAIA 52.8M
- IPO Year
- OMGA 2021
- MAIA 2022
- Fundamental
- Price
- OMGA $0.55
- MAIA $2.00
- Analyst Decision
- OMGA Strong Buy
- MAIA
- Analyst Count
- OMGA 5
- MAIA 0
- Target Price
- OMGA $9.20
- MAIA N/A
- AVG Volume (30 Days)
- OMGA 278.9K
- MAIA 346.7K
- Earning Date
- OMGA 11-14-2024
- MAIA 11-12-2024
- Dividend Yield
- OMGA N/A
- MAIA N/A
- EPS Growth
- OMGA N/A
- MAIA N/A
- EPS
- OMGA N/A
- MAIA N/A
- Revenue
- OMGA $8,095,000.00
- MAIA N/A
- Revenue This Year
- OMGA $181.38
- MAIA N/A
- Revenue Next Year
- OMGA N/A
- MAIA N/A
- P/E Ratio
- OMGA N/A
- MAIA N/A
- Revenue Growth
- OMGA 185.04
- MAIA N/A
- 52 Week Low
- OMGA $0.52
- MAIA $1.17
- 52 Week High
- OMGA $4.46
- MAIA $5.99
- Technical
- Relative Strength Index (RSI)
- OMGA 29.98
- MAIA 44.72
- Support Level
- OMGA $0.52
- MAIA $1.97
- Resistance Level
- OMGA $0.67
- MAIA $2.44
- Average True Range (ATR)
- OMGA 0.09
- MAIA 0.20
- MACD
- OMGA -0.02
- MAIA 0.00
- Stochastic Oscillator
- OMGA 5.95
- MAIA 8.33
About OMGA Omega Therapeutics Inc.
Omega Therapeutics Inc is a development-stage biotechnology company leveraging its proprietary epigenomic programming platform to biologically engineer a new class of programmable epigenetic medicines, known as Omega Epigenomic Controllers. Using epigenomic controllers, Omega is seeking to transform the practice of human medicine through selective and direct control of the human genome to treat and cure disease. It operates in the U.S.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company. The company develops targeted immunotherapies for cancer. The company is an immune-oncology company, focused on the development of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. The company's program is THIO, a potential cancer telomere-targeting agent in clinical development for the treatment of telomerase-positive cancer cells.